학술논문

Crystal structure of a conformational antibody that binds tau oligomers and inhibits pathological seeding by extracts from donors with Alzheimer's disease.
Document Type
article
Source
The Journal of biological chemistry. 295(31)
Subject
Humans
Alzheimer Disease
tau Proteins
Crystallography
X-Ray
Protein Multimerization
Single-Chain Antibodies
Alzheimer disease
amyloid
antibody
antibody engineering
fibril
inhibitor
neurodegeneration
neurodegenerative disease
oligomerization
prion
protein aggregation
protein crystallization
protein structure
tau
tauopathy
Neurosciences
Acquired Cognitive Impairment
Aging
Brain Disorders
Dementia
Neurodegenerative
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Alzheimer's Disease
5.1 Pharmaceuticals
2.1 Biological and endogenous factors
Aetiology
Development of treatments and therapeutic interventions
Neurological
Chemical Sciences
Biological Sciences
Medical and Health Sciences
Biochemistry & Molecular Biology
Language
Abstract
Soluble oligomers of aggregated tau accompany the accumulation of insoluble amyloid fibrils, a histological hallmark of Alzheimer disease (AD) and two dozen related neurodegenerative diseases. Both oligomers and fibrils seed the spread of Tau pathology, and by virtue of their low molecular weight and relative solubility, oligomers may be particularly pernicious seeds. Here, we report the formation of in vitro tau oligomers formed by an ionic liquid (IL15). Using IL15-induced recombinant tau oligomers and a dot blot assay, we discovered a mAb (M204) that binds oligomeric tau, but not tau monomers or fibrils. M204 and an engineered single-chain variable fragment (scFv) inhibited seeding by IL15-induced tau oligomers and pathological extracts from donors with AD and chronic traumatic encephalopathy. This finding suggests that M204-scFv targets pathological structures that are formed by tau in neurodegenerative diseases. We found that M204-scFv itself partitions into oligomeric forms that inhibit seeding differently, and crystal structures of the M204-scFv monomer, dimer, and trimer revealed conformational differences that explain differences among these forms in binding and inhibition. The efficiency of M204-scFv antibodies to inhibit the seeding by brain tissue extracts from different donors with tauopathies varied among individuals, indicating the possible existence of distinct amyloid polymorphs. We propose that by binding to oligomers, which are hypothesized to be the earliest seeding-competent species, M204-scFv may have potential as an early-stage diagnostic for AD and tauopathies, and also could guide the development of promising therapeutic antibodies.